Medtronic Expands Pain Portfolio with Merit Medical's ViaVerte BVNA System
Event summary
- Medtronic has entered a distribution agreement with Merit Medical Systems to offer the FDA-cleared ViaVerte BVNA system for chronic vertebrogenic lower-back pain.
- The ViaVerte system is the first and only BVNA system with a physician-controlled steerable mechanism for precise basivertebral nerve targeting.
- The agreement expands Medtronic's pain interventions portfolio and builds on an existing relationship with Merit Medical.
- The ViaVerte system will be available later in 2026 and offers a minimally invasive, same-day outpatient procedure.
- Medtronic's pain therapy portfolio includes spinal cord stimulation, vertebral augmentation, nerve ablation, bone tumor ablation, and targeted drug delivery.
The big picture
Medtronic's agreement with Merit Medical Systems underscores its strategy to strengthen its core franchises through strategic partnerships. The deal expands Medtronic's pain interventions portfolio, addressing the growing demand for innovative therapies in the chronic pain market. With one in three Americans suffering from chronic pain, the ViaVerte system represents a significant advancement in the BVNA market, offering a minimally invasive solution for patients with chronic vertebrogenic lower-back pain.
What we're watching
- Market Adoption
- The pace at which the ViaVerte system gains traction in the rapidly growing BVNA market.
- Strategic Integration
- How Medtronic integrates the ViaVerte system into its existing pain interventions portfolio.
- Competitive Dynamics
- Whether this partnership strengthens Medtronic's leadership in the chronic pain treatment space.
Related topics